CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The company is headquartered in Waltham, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). The company also exploring its utility in ameliorating complications of CKD. The company is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.

Industry: Pharmaceutical Preparations Peers: Amphastar Pharmaceuticals, Inc. Amylyx Pharmaceuticals Inc Relmada Therapeutics Inc Johnson & Johnson NGM BIOPHARMACEUTICALS INC Pliant Therapeutics Inc Tilray Brands Inc